How can the personal discovery process evolve personalized medicine? An interview with Laura Towart.

Clicks: 355
ID: 44845
2019
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
Laura is the Founder and CEO of My Personal Therapeutics, a London-based digital health company offering the most advanced personalized cancer therapeutics. She is also the Founder and former CEO of Celmatix, a leader in diagnostics and predictive analytics for female infertility and women's health. She is a graduate of the Weill Cornell Graduate School of Medical Sciences and Memorial Sloan Kettering Cancer Center's Doctoral program and received a Certificate in Bioinformatics. She holds a BS/BA in Biology/English from The George Washington University. Besides being passionate about personalized medicine, she enjoys exploring the world with her children Julian, Valentina and Delphine.
Reference Key
a-towart2019howpersonalized Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors A Towart, Laura;
Journal personalized medicine
Year 2019
DOI
10.2217/pme-2019-0087
URL
Keywords
Cancer artificial intelligence Machine learning personalized medicine colorectal cancer genomics big data precision medicine cancer research health artificial intelligence precision cancer

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.